November 30 2023 - AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Biopharma’s top 5 IPOs of 2023 so far
Astellas builds case for menopause drug fezolinetant
Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud